Global COVID-19 Vaccine Market Size to Exceed USD 42.66 Billion by 2035 | CAGR of 10.48%

Global COVID-19 Vaccine Market Size to Exceed USD 42.66 Billion by 2035

According to a Research Report Published by Decisions Advisors & Consulting, The Global COVID-19 Vaccine Market Size is expected to Grow from USD 14.25 Billion in 2024 to USD 42.66 Billion by 2035, at a CAGR of 10.48% during the forecast period 2025-2035.  

Browse 210 Market Data Tables And 45 Figures Spread Through 190 Pages and In-Depth TOC On the Global COVID-19 Vaccine Market Size, Share, and COVID-19 Impact Analysis, By Technology (mRNA Vaccines, Viral Vector Vaccines, and Others), By End User (Government, Hospitals & Clinics, Retail & Chain Pharmacies, and Others), and By Region (North America, Europe, Asia-Pacific, Latin America, Middle East, and Africa), Analysis and Forecast 2025 – 2035. Get Detailed Report Description Here: https://www.decisionsadvisors.com/reports/covid-19-vaccine-market                 

The worldwide sector is focused on the research, manufacturing, distribution, and marketing of vaccines aimed at preventing SARS-CoV-2 infection. COVID-19 vaccines are medical products developed to protect individuals from the novel coronavirus (SARS-CoV-2) responsible for COVID-19. Vaccinations lower the likelihood of severe illness or fatalities from COVID-19 by training the immune system to recognise and fight the virus. Globally, several COVID-19 vaccines, including those produced by Pfizer-BioNTech, Moderna, AstraZeneca-Oxford, and others, have been created and authorised for emergency use. The primary COVID vaccines are mRNA and viral vector types. These vaccines instruct the body to generate an immune response against the virus through various technologies, such as messenger RNA (mRNA) and adenoviral vectors. Additionally, to ensure their efficacy and safety, vaccines have been subjected to rigorous testing during clinical trials. Market players are observing growth opportunities as the demand for booster shots increases to sustain immunity against emerging virus variants. Additionally, because of the significant rise in cases and the increase in vaccination rates globally, the COVID-19 vaccine sector entered a phase of steady growth. The COVID-19 vaccine market faces various challenges, including reduced demand after the pandemic, vaccine hesitancy, logistical distribution issues, regulatory hurdles, and competition from other treatment options.

The mRNA vaccines segment accounted for the largest share in 2024 and is anticipated to grow at a significant CAGR during the forecast period.       

Based on the technology, the COVID-19 vaccine market is segmented into mRNA vaccines, viral vector vaccines, and others. Among these, the mRNA vaccines segment accounted for the largest share in 2024 and is anticipated to grow at a significant CAGR during the forecast period. With a straightforward production method, the mRNA vaccines are highly effective at eliciting an immune response; some of them have efficacy rates comparable to those of other vaccines. mRNA vaccines can be produced more rapidly and affordably.

The government segment dominated the market in 2024 and is projected to grow at a significant CAGR during the forecast period.     

Based on the end user, the COVID-19 vaccine market is divided into government, hospitals & clinics, retail & chain pharmacies, and others. Among these, the government segment dominated the market in 2024 and is projected to grow at a significant CAGR during the forecast period. Governments have made large financial investments in the development, testing, and distribution of vaccines in an effort to stop the epidemic. This funding has been essential in hastening the development of vaccines and ensuring their timely accessibility to the general public.

Asia Pacific is expected to hold the majority share of the global COVID-19 vaccine market during the forecast period.       

Asia Pacific is expected to hold the majority share of the global COVID-19 vaccine market during the forecast period. This is because of its large population base, dense population, and early viral exposure, all of which led to quick community spread. Government-led public health initiatives, including comprehensive testing programs, funding for emergency medical care, and accelerated regulatory clearances, also contributed to the prompt application of diagnostic solutions.

North America is anticipated to grow at the fastest pace in the global COVID-19 vaccine market during the forecast period. This is due to the early and widespread nature of the outbreak, which created an urgent need for comprehensive disease monitoring and diagnostic testing. Additionally, the region benefited from significant government support in the form of emergency money, testing mandates, and accelerated regulatory clearances, as well as a well-established healthcare infrastructure and rapid adoption of state-of-the-art molecular diagnostics like PCR.

Major vendors in the global COVID-19 vaccine market are AstraZeneca, Bharat Biotech, CanSino Biologics, CureVac, Gamaleya Research Institute, GlaxoSmithKline, Johnson & Johnson, Moderna, Novavax, Pfizer-BioNTech, Sanofi-GSK, Serum Institute of India, Sinopharm, Sinovac, and Others.

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting and Research Firm
• Venture capitalists
• Value-Added Resellers (VARs)

Recent Development   

• In December 2025, the Ministry of Food and Drug Safety (MFDS) in South Korea permitted GC Biopharma to start Phase 1 clinical trials of its COVID-19 mRNA vaccine candidate, GC4006A. This is an important turning point in Korea's efforts to boost pandemic preparedness and localise mRNA vaccine technology.

Market Segment  

This study forecasts revenue at global, regional, and country levels from 2020 to 2035. Decisions Advisors has segmented the COVID-19 vaccine market based on the below-mentioned segments: 

Global COVID-19 Vaccine Market, By Technology

• mRNA Vaccines
• Viral Vector Vaccines
• Others

Global COVID-19 Vaccine Market, By End User

• Government
• Hospitals & Clinics
• Retail & Chain Pharmacies
• Others

Global COVID-19 Vaccine Market, By Regional Analysis

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Rest of Asia Pacific
• South America
  • Brazil
  • Argentina
  • Rest of South America
• Middle East & Africa
  • UAE
  • Saudi Arabia
  • Qatar
  • South Africa
  • Rest of the Middle East & Africa